Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

BACKGROUND: RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalimuddin, Shirin, Tham, Christine Y.L., Qui, Martin, de Alwis, Ruklanthi, Sim, Jean X.Y., Lim, Joey M.E., Tan, Hwee-Cheng, Syenina, Ayesa, Zhang, Summer L., Le Bert, Nina, Tan, Anthony T., Leong, Yan Shan, Yee, Jia Xin, Ong, Eugenia Z., Ooi, Eng Eong, Bertoletti, Antonio, Low, Jenny G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030737/
https://www.ncbi.nlm.nih.gov/pubmed/33851143
http://dx.doi.org/10.1016/j.medj.2021.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030737/
https://www.ncbi.nlm.nih.gov/pubmed/33851143
http://dx.doi.org/10.1016/j.medj.2021.04.003

Ejemplares similares